Kinvard Bio
Pre-clinicalKinvard Bio has developed a novel class of broad-spectrum, bacterial ribosome-targeting oxepanoprolinamide antibiotics to treat acute and chronic drug-resistant infections.
Founded
1990
Focus
Small Molecules
About
Kinvard Bio has developed a novel class of broad-spectrum, bacterial ribosome-targeting oxepanoprolinamide antibiotics to treat acute and chronic drug-resistant infections.
Company Info
TypePrivate
Founded1990
LocationCambridge, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile